Cardiac and Liver Crosstalk in Fibrosis: Who Is the "Brains" of the Operation?
Nov
08
2025
Convention Center: Room 146C, Level 1
8:00 AM - 9:30 AM
World Class Speakers
Description
Cardiovascular disease is the leading cause of death among patients with MASH. The mechanisms by which liver fibrosis due to MASH promotes cardiovascular disease are not clear. Moreover, emerging data suggest that cardiac disease may promote liver fibrosis progression. In this session, speakers provide a clinical overview of the association between MASH-related fibrosis/cirrhosis and cardiovascular disease, and dissect potential underlying mechanisms.Journey Maps
Presentations
8:00 AM - 8:15 AM
Nov
08
2025
Washington, D.C.
Common Fibrotic Mechanisms Between the Liver and the Heart
Leila Gobejishvili, Presenter
Basic Science
8:15 AM - 8:30 AM
Nov
08
2025
Washington, D.C.
Association of Metabolic Dysfunction-Associated Steatohepatitis Fibrosis With Cardiovascular Outcomes
Kathleen E Corey, MD, MPH, MMSc, Presenter
Basic Science
8:30 AM - 8:45 AM
Nov
08
2025
Washington, D.C.
Cardiovascular Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: Dissecting Molecular Mechanisms
David A Brenner, MD, Presenter
Basic Science
8:45 AM - 9:00 AM
Nov
08
2025
Washington, D.C.
It Is Not What but How: Differing Mechanisms of Liver Fat Accumulation Are Associated With Different Cardiovascular Risk
Hanieh Yaghootkar, Presenter
Basic Science
Objectives
- Explain how liver fibrosis impacts cardiovascular disease.
- Review the impact of cardiovascular disease on liver fibrosis.
- Discuss how genetics inform mechanisms of hepatic steatosis and predict liver and cardiovascular outcomes.
Chair
Meena B Bansal, MD, FAASLD
Icahn School of Medicine at Mount Sinai (ISMMS)